Corcept

Corcept Stock Crashes 20% as Genmab's Rina-S Posts Landmark Phase 3 Results in Ovarian Cancer

2026-10-24

Corcept stock fell 20.13% on Friday, October 23, 2026 — because a rival's drug just posted standout Phase 3 results in the exact cancer market Corcept entered this year. Corcept Therapeutics (NASDA...